BLAINJECTIONINJECTABLE
Approved
Jun 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
5/8 — Partial
NULOJIX (belatacept) by Bristol Myers Squibb is cd80-directed antibody interactions [moa]. Approved for selective t cell costimulation blocker [epc]. First approved in 2011.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NULOJIX (belatacept) is a fusion protein that selectively blocks T cell costimulation by targeting CD80/CD86 interactions, preventing T cell activation. It is indicated for prevention of organ rejection in adult patients receiving a kidney transplant. The drug works by interrupting the second signal required for full T cell activation, thereby reducing the risk of acute and chronic rejection.
$0.005BPart D
PeakStable
NULOJIX is in peak commercial stage with modest Part D penetration (~2,349 claims in 2023), indicating a stable but narrow specialist market requiring focused kidney transplant field coverage.
Mechanism of Action
CD80-directed Antibody Interactions
Pharmacologic Class:
Selective T Cell Costimulation Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Belatacept in Heart Transplantation
Started Jan 2025
66 enrolled
Heart Transplant
The Safety/Efficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation
Started Jan 2022
5 enrolled
SensitisationHighly Sensitised Dialysis Patients
Carfilzomib and Belatacept for Desensitization
Started Dec 2021
21 enrolled
Highly Sensitized Prospective Kidney Transplant Recipients
Daratumumab and Belatacept for Desensitization
Started Nov 2021
19 enrolled
Highly Sensitized Prospective Kidney Transplant Recipients
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Started Jul 2021
102 enrolled
Renal Allograft Recipients
Worked on NULOJIX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.